FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124886670> ?p ?o ?g. }

• W2124886670 endingPage "285" @default.
• W2124886670 startingPage "280" @default.
• W2124886670 abstract "OBJECTIVE Type 2 diabetes accompanied by renal damage is a strong risk factor for atherosclerotic events. The purpose of this study was to investigate the efficacy of low-dose aspirin therapy on primary prevention of atherosclerotic events in patients with type 2 diabetes and coexisting renal dysfunction. RESEARCH DESIGN AND METHODS The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial was a prospective, randomized, open-label trial conducted throughout Japan that enrolled 2,539 type 2 diabetic patients without a history of atherosclerotic diseases. Patients were assigned to the aspirin group (81 mg/day or 100 mg/day) or the nonaspirin group and followed for a median of 4.37 years. The primary end points were atherosclerotic events of fatal and nonfatal ischemic heart disease, stroke, and peripheral arterial disease. RESULTS The analysis included 2,523 patients who had serum creatinine measured. In 1,373 patients with baseline estimated glomerular filtration rate (eGFR) 60–89 mL/min/1.73 m2, the incidence of primary end points was significantly lower in the aspirin group than in the nonaspirin group (aspirin, 30/661; nonaspirin, 55/712; hazard ratio 0.57 [95% CI 0.36–0.88]; P = 0.011). Low-dose aspirin therapy did not reduce primary end points in patients with eGFR ≥90 mL/min/1.73 m2 (aspirin, 9/248; nonaspirin, 11/270; 0.94 [0.38–2.3]) or those with eGFR &lt;60 mL/min/1.73 m2 (aspirin, 29/342; nonaspirin, 19/290; 1.3 [0.76–2.4]). The Cox proportional hazard model demonstrated a significant interaction between mild renal dysfunction (eGFR 60–89 mL/min/1.73 m2) and aspirin (P = 0.02). CONCLUSIONS These results suggest a differential effect of low-dose aspirin therapy in diabetic patients with eGFR 60–89 mL/min/1.73 m2." @default.
• W2124886670 created "2016-06-24" @default.
• W2124886670 creator A5000358315 @default.
• W2124886670 creator A5015115080 @default.
• W2124886670 creator A5020090012 @default.
• W2124886670 creator A5045410612 @default.
• W2124886670 creator A5047881217 @default.
• W2124886670 creator A5048525796 @default.
• W2124886670 creator A5049895325 @default.
• W2124886670 creator A5066956159 @default.
• W2124886670 creator A5075403819 @default.
• W2124886670 creator A5078052739 @default.
• W2124886670 creator A5080185082 @default.
• W2124886670 creator A5089093718 @default.
• W2124886670 date "2011-01-20" @default.
• W2124886670 modified "2023-10-16" @default.
• W2124886670 title "Low-Dose Aspirin Therapy in Patients With Type 2 Diabetes and Reduced Glomerular Filtration Rate" @default.
• W2124886670 cites W1539575618 @default.
• W2124886670 cites W1983568514 @default.
• W2124886670 cites W1986003353 @default.
• W2124886670 cites W2011453015 @default.
• W2124886670 cites W2011863243 @default.
• W2124886670 cites W2016046345 @default.
• W2124886670 cites W2050820265 @default.
• W2124886670 cites W2051340399 @default.
• W2124886670 cites W2073076025 @default.
• W2124886670 cites W2075123078 @default.
• W2124886670 cites W2100089051 @default.
• W2124886670 cites W2102191497 @default.
• W2124886670 cites W2102397849 @default.
• W2124886670 cites W2116148738 @default.
• W2124886670 cites W2138597449 @default.
• W2124886670 cites W2152189242 @default.
• W2124886670 cites W2162985177 @default.
• W2124886670 cites W2180664789 @default.
• W2124886670 cites W2626017884 @default.
• W2124886670 cites W4245466284 @default.
• W2124886670 cites W4248176882 @default.
• W2124886670 doi "https://doi.org/10.2337/dc10-1615" @default.
• W2124886670 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3024334" @default.
• W2124886670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21270185" @default.
• W2124886670 hasPublicationYear "2011" @default.
• W2124886670 type Work @default.
• W2124886670 sameAs 2124886670 @default.
• W2124886670 citedByCount "39" @default.
• W2124886670 countsByYear W21248866702012 @default.
• W2124886670 countsByYear W21248866702013 @default.
• W2124886670 countsByYear W21248866702014 @default.
• W2124886670 countsByYear W21248866702015 @default.
• W2124886670 countsByYear W21248866702016 @default.
• W2124886670 countsByYear W21248866702017 @default.
• W2124886670 countsByYear W21248866702018 @default.
• W2124886670 countsByYear W21248866702019 @default.
• W2124886670 countsByYear W21248866702020 @default.
• W2124886670 countsByYear W21248866702021 @default.
• W2124886670 countsByYear W21248866702022 @default.
• W2124886670 countsByYear W21248866702023 @default.
• W2124886670 crossrefType "journal-article" @default.
• W2124886670 hasAuthorship W2124886670A5000358315 @default.
• W2124886670 hasAuthorship W2124886670A5015115080 @default.
• W2124886670 hasAuthorship W2124886670A5020090012 @default.
• W2124886670 hasAuthorship W2124886670A5045410612 @default.
• W2124886670 hasAuthorship W2124886670A5047881217 @default.
• W2124886670 hasAuthorship W2124886670A5048525796 @default.
• W2124886670 hasAuthorship W2124886670A5049895325 @default.
• W2124886670 hasAuthorship W2124886670A5066956159 @default.
• W2124886670 hasAuthorship W2124886670A5075403819 @default.
• W2124886670 hasAuthorship W2124886670A5078052739 @default.
• W2124886670 hasAuthorship W2124886670A5080185082 @default.
• W2124886670 hasAuthorship W2124886670A5089093718 @default.
• W2124886670 hasBestOaLocation W21248866701 @default.
• W2124886670 hasConcept C126322002 @default.
• W2124886670 hasConcept C126894567 @default.
• W2124886670 hasConcept C127413603 @default.
• W2124886670 hasConcept C134018914 @default.
• W2124886670 hasConcept C141071460 @default.
• W2124886670 hasConcept C159641895 @default.
• W2124886670 hasConcept C207103383 @default.
• W2124886670 hasConcept C2777180221 @default.
• W2124886670 hasConcept C2777628954 @default.
• W2124886670 hasConcept C2778653478 @default.
• W2124886670 hasConcept C2780306776 @default.
• W2124886670 hasConcept C2780645631 @default.
• W2124886670 hasConcept C44249647 @default.
• W2124886670 hasConcept C50440223 @default.
• W2124886670 hasConcept C555293320 @default.
• W2124886670 hasConcept C71924100 @default.
• W2124886670 hasConcept C78519656 @default.
• W2124886670 hasConcept C90924648 @default.
• W2124886670 hasConceptScore W2124886670C126322002 @default.
• W2124886670 hasConceptScore W2124886670C126894567 @default.
• W2124886670 hasConceptScore W2124886670C127413603 @default.
• W2124886670 hasConceptScore W2124886670C134018914 @default.
• W2124886670 hasConceptScore W2124886670C141071460 @default.
• W2124886670 hasConceptScore W2124886670C159641895 @default.
• W2124886670 hasConceptScore W2124886670C207103383 @default.
• W2124886670 hasConceptScore W2124886670C2777180221 @default.
• W2124886670 hasConceptScore W2124886670C2777628954 @default.

• next